"Old" Antibiotics Face More Generic Pressure After FDA Denies 30-Month Stays
This article was originally published in The Pink Sheet Daily
Executive Summary
Teva's brief at-risk launch of the acne product Solodyn followed by a settlement with Medicis may serve as template.